Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20079280 | 0.86 | CYP2C19 (0.35) | ADH1BADH1CADH1AALDH1A1CYP1A2 | |
| SCHEMBL7778093 | 0.84 | ADH1B (0.39) | LMNAADH1BADH1CADH1AALDH1A1 | |
| SCHEMBL17088076 | 0.83 | TSHR (0.39) | ADH1BADH1CADH1AALDH1A1CYP1A2 | |
| SCHEMBL7863936 | 0.81 | ALDH1A1 (0.39) | ADH1BADH1CADH1AALDH1A1CYP1A2 | |
| SCHEMBL19254391 | 0.80 | ADH1B (0.33) | ADH1BADH1CADH1AALDH1A1CYP1A2 | |
| SCHEMBL21322187 | 0.79 | ALDH1A1 (0.30) | ADH1BADH1CADH1AALDH1A1CYP1A2 | |
| SCHEMBL23189474 | 0.79 | ADH1B (0.36) | ADH1BADH1CADH1AALDH1A1CYP1A2 | |
| SCHEMBL85952 | 0.78 | ANPEP (0.33) | ADH1BADH1CADH1AALDH1A1CYP1A2 | |
| SCHEMBL25600405 | 0.78 | ACE2 (0.41) | LMNAADH1BADH1CADH1AALDH1A1 | |
| SCHEMBL18244860 | 0.76 | ADH1B (0.38) | ADH1BADH1CADH1AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | LMNA 2823/4885ADH1B 3408/4885ADH1C 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.